PowerPoint Presentationsuper7/10011-11001/10811.… · PPT file · Web view · 2003-07-19Title:...
Transcript of PowerPoint Presentationsuper7/10011-11001/10811.… · PPT file · Web view · 2003-07-19Title:...
Adeel A. Butt, MD
* P < 0.001
0
10
20
30
40
50
60
80
28%
69%*
70
End of treatment
Sustained
39%*
19%
IFN a-2a 6/3 MIUPEGASYS™ 180 µg
Response(%)
Standard Interferon vs. Pegylated Interferon
* Intent-to-treat population
Adeel A. Butt, MDZeuzem et al. NEJM 2000; 343:1666-1672
Standard Interferon vs. Pegylated Interferon
0
10
20
30
40
Patie
nts w
ith R
espo
nse
(%)
7%
28%
IFN -2a PEG -IFN
Genotype 1
Adeel A. Butt, MD
0
10
20
30
40
50
60
Patie
nts w
ith R
espo
nse
(%)
37%
56%
IFN-2a PEG -IFN
Zeuzem et al. NEJM 2000; 343:1666-1672
Standard Interferon vs. Pegylated Interferon
Genotype 2,3
Adeel A. Butt, MD
IFN IFN -2b-2b+ RBV+ RBV
(n = 444)(n = 444)
PEG-IFN PEG-IFN -2a-2a+ Placebo+ Placebo(n = 224)(n = 224)
PEG alone vs. IFN+RBV vs. PEG+RBV
PEG-IFN PEG-IFN -2a-2a+ RBV+ RBV
(n = 453)(n = 453)
Age (mean, y)Age (mean, y) 42.342.3 42.442.4 42.842.8Male GenderMale Gender 68%68% 73%73% 71%71%Weight (kg)Weight (kg) 78.978.9 78.178.1 79.679.6GenotypeGenotype 11 64%64% 64%64% 66%66% 2 and 32 and 3 31%31% 33%33% 31%31%HCV RNA TitersHCV RNA Titers(mean, 10(mean, 1066 c/mL) c/mL) 5.95.9 6.06.0 6.16.1CirrhosisCirrhosis 15%15% 12%12% 12%12%
Fried MW et al. NEJM 2002
Adeel A. Butt, MD
PEG alone vs. IFN+RBV vs. PEG+RBVSustained Virologic Response
n = 224
n = 444
n = 45330%
56%
45%
0%
20%
40%
60%
% P
atie
nts
IFN -2b + RBV
PEG-IFN -2a+ Placebo
PEG-IFN -2a+ RBV
P = 0.001 for all comparisons
Fried MW et al. NEJM 2002
Adeel A. Butt, MD
% o
f Pat
ient
s
0
10
20
30
40
50
60
70
80
Genotype 1 Genotype 2, 3
n = 285n = 298
37%
21%
46%
n = 145
n = 145n = 140
61%45%
76%
n = 69
PEG alone vs. IFN+RBV vs. PEG+RBVSustained Virologic Response by Genotype
PEG-IFN -2a + PlaceboIFN -2b + RBV PEG-IFN -2a + RBV
P = 0.001
P = 0.054 P = 0.008P = 0.001
P = 0.001 P = 0.016
Adeel A. Butt, MD
IFN+RBV vs. Low Dose PEG+RBV vs. High Dose PEG+RBV
47 4754
0
20
40
60
80
IFN alfa-2b 3 MIU TIW + RBV
1000-1200 mg
SV
R (%
)
PEG (12 kDa) IFN alfa-2b
1.5 / 0.5 g/kg+ RBV 1000-1200 mg
PEG (12 kDa) IFN alfa-2b
1.5 g/kg+ RBV 800 mg
P = .01
Manns et al. Lancet. 2001;358:958-965.
(n = 511)(n = 505) (n = 514)
P = .73
Adeel A. Butt, MD
Adeel A. Butt, MD
Side Effects of IFNFlu-like symptoms
Headache Fatigue or asthenia Myalgia, arthralgia Fever, chills
Nausea Diarrhea Alopecia Thyroiditis
Psychiatric symptoms Depression Mood lability
Injection site reaction Autoimmunity Lab alterations
Neutropenia Anemia Thrombocytopenia
Adeel A. Butt, MD
Side Effects of RBV
Hemolytic anemia Teratogenicity Cough and dyspnea Rash and pruritus Insomnia Anorexia
Rebetron [package insert]. Kenilworth, NJ: Schering Corp; 1999.
Adeel A. Butt, MD
PEG (12 kDa) IFN alfa-2b Incidence of Discontinuations Due to Adverse Events
0
2
4
6
8
10
12
1414
IFN = interferon; PEG = polyethylene glycol; RBV = ribavirin.
1313
PEG IFN alfa-2b (12 kDa) 1.5 µg/kg + RBV
PEG IFN alfa-2b (12 kDa)
1.5/0.5 µg/kg + RBV
IFN alfa-2b + RBV
Per
cent
HCV-HIV Co-infection
Adeel A. Butt, MD
HCV and HIV - Similarities
+ ssRNA – Flavivirus Virions/d = 1012
Diversity/complexity Six genotypes
Tropism: hepatocyte Receptors: LDL, CD81
+ ssRNA – Retrovirus Virions/d = 1010 - 1011
Diversity/complexity 11+ clades
Tropism: lymphoid Receptors: CD4, CCR5
HIV
CCR5 = chemokine receptor 5; CD4 = cluster of deviation 4; CD81 = cluster of deviation 81; LDL = low density lipoprotein; + ssRNA = positive single strand ribonucleic acid.
HCVHCV HIV
Adeel A. Butt, MD
HCV and HIV
Prevalence of HCV in HIV > 10x general population
Reported to be between 30-50%
~6% of VA population HCV infected
~35-43% of HIV infected veterans have HCV
Greub, Lancet 2000;356:1800-5
Adeel A. Butt, MD
Hepatitis C Virus and HIV Liver-Related Mortality
UK hemophilia population, 1985-1998
Deaths due to liver disease
• HIV - 16.7-fold• HIV + 94.4-fold
Risk after 10 years
0
20
40
60
80
HIV+ HIV- GP
GP = general population; HIV = human immunodeficiency virus; O/E = observed to expected.
Dea
ths
Due
to L
iver
Dis
ease
Dea
ths
Due
to L
iver
Dis
ease
(O/E
)(O
/E)
Adeel A. Butt, MD
Increasing Mortality From ESLD in Patients With HIV
One third of 1998 cohort had recent history of discontinuing HAART secondary to hepatotoxicity
More than 1/2 who died with ESLD had either NDVL or CD4 >200/mm3 6 months prior to death
ES
LD-R
elat
ed D
eath
s (%
)
199119961998
50
40
30
20
10
0
1114
50
ESLD = end stage liver disease; NDVL = no detectable viral load.
Adeel A. Butt, MD
HCV-HIV Co-infection
Progression of liver disease accelerated in HCV-HIV co-infected patients
Median time to cirrhosis 7 years in HCV-HIV vs. 23 years in HCV alone
Soto, J Hepatol 1997;26:1-5
11,5
75
13,9
57,750
93,8
0102030405060708090
100
1991 1996 1998-99
Deaths related toESLD% of ESLD deaths whowere HCV positive
Adeel A. Butt, MD
HCV-HIV Co-infection
Generally no increase in HIV progression
No difference in survival, progression from HIV to AIDS or AIDS to death or HIV to death
Rate of decline of CD4 counts is also similar
Dorrucci, JID 1995;172:1503-8Staples Clin Infect Dis
1998;29:150-4Sulkowski JAMA 2002
More AIDS at baseline
More progression Decreased CD4
recovery
Greub, Lancet 2002 De Luca, Archives
2002
Effect of HCV on HIV Progression
CONTROVERSIAL
Adeel A. Butt, MD
PEG-IFN + RBV is associated with a superior week 24 virologic response (VR)
Overall Wk 24 VR* 10 (15%) 29 (44%) 0.0003genotype 1** 4/52 (7%) 17/51 (33%) 0.0014genotype non-1** 6/15 (40%) 12/15 (80%) 0.06biochemical response 44% 54% NS
IFN + R PEGIFN + R n=67 n=66 p value
*intent to treat **Genotype 1 vs. non-1, p < 0.0001
Slide courtesy of R. Chung
Adeel A. Butt, MD
A significant portion of virologic nonresponders experience histologic response (HR)
Virologic nonresponders 57 (85%) 37 (56%) 0.0003Wk 24 Bx obtained 37 23Histologic response 15 (40%) 6 (26%) 0.28
Combined virologic and histologic responseVR + HR 25 (37%) 35 (53%) 0.08
IFN + R PEGIFN + R n=67 n=66 p value
Slide courtesy of R. Chung
Adeel A. Butt, MD
Grade 4 events
Grade 0-1 18 9 NSGrade 2 25 18 NSGrade 3 20 22 NSGrade 4 4 17 0.0012
ANC (< 500) 3 7 NSgluc (> 500) 0 4 NSplt (< 20K) 0 1 NSLFTs (> 10x ULN) 0 2 NSdepression 1 0 NS
Premature D/C 8 (12%) 8 (12%) NS
IFN + R PEGIFN + R n = 67 n = 66 p
value
Slide courtesy of R. Chung
Adeel A. Butt, MD
Absolute CD4 fell but CD4% rose
Wk 0 CD4 452 500 0.07%CD4 24.0 25.5 0.19
Wk 24 CD4 369 363 0.80%CD4 27.0 30.5 0.10CD4 W0-24 -112 -194 0.01%CD4 W0-24* +2.5% +3.5% 0.14
IFN + R PEGIFN + R p value
*overall +3.0%, p = 0.0001
Slide courtesy of R. Chung
Adeel A. Butt, MD
There was no adverse effect on HIV-1 control
W0 W24und und 59 (50%) 32 (52%) 27 (47%) NSund det 9 (8%) 6 (10%) 3 (5%) NSdet und 16 (13%) 6 (10%) 10 (5%) NSdet det 35 (29%) 18 (29%) 17 (30%) NSW0 undetectable 38 (62%) 30 (52%) NSW24 undetectable 38 (62%) 37 (65%) NS
HIV RNA Total IFN + R PEGIFN + R
n = 119 n = 62 n = 57
p
Slide courtesy of R. Chung
Adeel A. Butt, MD
HCV-HIV Co-infected Patients
51 patients IFN alfa 2b, 3 million units TIW PLUS
RBV 1000-1200 12 months 59% genotype 1 Cirrhosis – 55% Mean CD4 = 411
Landau. AIDS 2001;15:2149-2155.
Adeel A. Butt, MD
HCV-HIV Co-infected Patients
ETVR = 29% SVR = 21% CD4 drop at end of treatment = 51
normalized after 6 months Treatment discontinuation 29%
Landau. AIDS 2001;15:2149-2155.
Adeel A. Butt, MD
Hepatotoxicity in Co-infected Patients
May be more common in co-infected patients, esp. those on PI based regimens
However, overall risk small 88% co-infected patients on HAART had
NO toxicity Reversible in those in whom it occurred
Difficult to provide guidelines on management:
Stop or change therapy if liver enzymes > 3-5 times ULNSulkowski, JAMA 2000;283:74-80.
Adeel A. Butt, MD
Take psychiatric history for depression and mania Develop relationship with mental health providers Treat preexisting depression before starting (PEG) IFN Evaluate patients for development of depression at least
every 2 weeks after initiation of IFN therapy Mild depression – evaluate weekly Moderate depression – reduce dose of IFN; consider
psychiatric consultation PEG IFN alfa-2a: reduce to 135 µg weekly PEG IFN alfa-2b: reduce dose by 1/2
Severe depression – discontinue IFN/RBV immediately and permanently; obtain immediate psychiatric consult
Managing Depression
Adeel A. Butt, MD
Neutropenia Consider G-CSF 300 µg SC BIW or TIW No controlled trials demonstrating effectiveness Clinical experience shows this to be effective ANC <750 cells/mm3 – dose reduce IFN
PEG IFN alfa-2a: decrease to 135 µg weekly PEG IFN alfa-2b: decrease dose by 1/2
ANC <500 cells/mm3 – discontinue IFN
Management of Neutropenia
GCSF = granulocyte-colony stimulating factor.
Adeel A. Butt, MD
Management of RBV-Induced Anemia
Hemoglobin determinations pretreatment, at week 2, week 4, and as needed
If >10 g/dL: no action needed If <10 g/dL: reduce RBV dose to 600 mg daily If <8.5 g/dL: stop RBV If decreases by >2 g/dL from starting therapy:
reduce dose to 600 mg daily in patients with cardiac history Hemoglobin returns to baseline within 4 weeks after RBV is
stopped Cardiac function
Anemia may exacerbate symptoms of coronary disease and/or deteriorate cardiac function
Recommend stress test for patients aged >50 years Consider epoetin alfa 40,000 IU SC QW
Adeel A. Butt, MD
Conclusions HCV is a common disease and a frequent cause of morbidity
and mortality in the US and globally Current treatment options can eradicate/cure HCV in a
significant proportion of chronically infected patients Very few eligible patients actually receive treatment HCV co-infection is very common in the HIV infected patients Treatment is associated with significant adverse events, especially in the HCV-HIV co-infected patients Benefits of treatment should be weighed against the risks, considering the long natural history of the disease